Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CorVision® 4-year Follow-up (CorVision4yFU)

28. mai 2026 oppdatert av: Katerina Klimesova, Gemini Eye Clinic

Four Years Extended Follow-Up on CorVision® Bioengineered Corneal Microlens: Safety and Efficacy

The objective of the study is to assess the long-term safety and effectiveness of the CorVision® microlens implanted in presbyopic patients for the management of management of presbyopia and near vision impairment. Approximately 100 patients in the Czech Republic will participate in this study. The study was reviewed and approved by an independent research ethics committee and also by the State Institute for Drug Control (SÚKL). The study will consist of a single visit during which standard, non-invasive, and painless examinations will be performed. This visit will correspond to the 4-year follow-up visit of the original clinical trial.

Studieoversikt

Status

Fullført

Forhold

Studietype

Observasjonsmessig

Registrering (Faktiske)

95

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Tsjekkia
      • Zlín, Tsjekkia, 760 01
        • Gemini Eye Clinic

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The target population are patients who suffered from presbyopia and underwent the original CorVision clinical study are medically suitable to undertake the current clinical study investigation.

Beskrivelse

Inclusion Criteria:

  • Subjects must have undergone implantation of CorVision microlens under study protocol CMG-PRT-002.
  • Provide informed consent
  • Willing to participate in the ophthalmological examinations

Exclusion Criteria:

  • Patients with severe ocular or general disorders that would prevent them from completed the visit.
  • Patients not being able to understand and give informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Post-presbyopia correction with unilaterally implanted microlens
Presbyopic patients who have undergone implantation of the CorVision microlens according to study protocol CMG-PRT-002.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Uncorrected Near Visual Acuity of 0.3 logMAR or better
Tidsramme: At least 4 years after the implantation
More than 65% of the eyes should have an Uncorrected Near Visual Acuity (UNVA) of 0.3 logMAR or better at 4 years postoperatively.
At least 4 years after the implantation
Implant removal
Tidsramme: At least 4 years after the implantation
The incidence of implant rejection leading to implant removal should occur in no more than 3% of implanted eyes.
At least 4 years after the implantation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinically significant corneal haze occurrence
Tidsramme: At least 4 years after the implantation
Clinically significant corneal haze is defined as any new stromal clouding in or near the laser-created pocket that leads to a reduction in central corneal clarity/transparency, is visible upon slit-lamp examination, and is graded as ≥ 2 on a standardized corneal haze grading scale.
At least 4 years after the implantation

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Monocular Uncorrected Near Visual Acuity at Best Reading Distance
Tidsramme: At least 4 years after the implantation
Change in monocular uncorrected near visual acuity and best reading distance over time
At least 4 years after the implantation
Monocular and Binocular Uncorrected Near Visual Acuity at 40 cm
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Uncorrected Near Visual Acuity (UNVA) at 40 cm.
At least 4 years after the implantation
Monocular and Binocular Distance Corrected Near Visual Acuity
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Distance Corrected Near Visual Acuity (DCNVA).
At least 4 years after the implantation
Monocular and Binocular Corrected Near Visual Acuity
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Corrected Near Visual Acuity (CNVA) over time.
At least 4 years after the implantation
Monocular and Binocular Uncorrected Intermediate Visual Acuity (UIVA)
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Uncorrected Intermediate Visual Acuity (UIVA) over time.
At least 4 years after the implantation
Monocular and Binocular Distance Corrected Intermediate Visual Acuity
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Distance Corrected Intermediate Visual Acuity (DCIVA) over time.
At least 4 years after the implantation
Monocular and Binocular Uncorrected Distance Visual Acuity (UDVA)
Tidsramme: At least 4 years after the implantation
Change in monocular Uncorrected Distance Visual Acuity (UDVA) over time.
At least 4 years after the implantation
Monocular and Binocular Corrected Distance Visual Acuity (CDVA)
Tidsramme: At least 4 years after the implantation
Change in monocular and binocular Corrected Distance Visual Acuity (CDVA) over time.
At least 4 years after the implantation
Objective refraction
Tidsramme: At least 4 years after the implantation
Change in objective refractive sphere and cylinder magnitude measured by autorefractometry.
At least 4 years after the implantation
Subjective refraction
Tidsramme: At least 4 years after the implantation
Change in manifest refractive sphere and cylinder magnitude, measured in diopters (D).
At least 4 years after the implantation
Near addition
Tidsramme: At least 4 years after the implantation
Change in near addition values over time.
At least 4 years after the implantation
Corneal Keratometry Measurements (K1, K2, and Kmean)
Tidsramme: At least 4 years after the implantation

Change in corneal keratometry values, including K1, K2, and mean keratometry (Kmean), as measured by corneal topography over time.

Change in keratometry K1, K2 and Kmean measured in diopters over time.
At least 4 years after the implantation
Central Corneal Thickness (Pachymetry) Measurement
Tidsramme: At least 4 years after the implantation
Change in central corneal thickness as measured by corneal pachymetry over time.
At least 4 years after the implantation
Endothelial Cell Density (Study Eye)
Tidsramme: At least 4 years after the implantation
Change in endothelial cell density over time.
At least 4 years after the implantation
Intraocular Pressure (Study Eye)
Tidsramme: At least 4 years after the implantation
Change in intraocular pressure over time.
At least 4 years after the implantation
Tear Film Break-Up Time (TBUT) Test
Tidsramme: At least 4 years after the implantation
Change in tear film stability as measured by Tear Film Break-Up Time (TBUT) in units of seconds.
At least 4 years after the implantation
Tear Production (Schirmer Test)
Tidsramme: At least 4 years after the implantation
Change in tear production as measured by the Schirmer test in units of mm.
At least 4 years after the implantation
Corneal Thickness Measurement Using Optical Coherence Tomography (OCT)
Tidsramme: At least 4 years after the implantation
Change in corneal thickness measured at the corneal center in μm.
At least 4 years after the implantation
Abnormal findings at OCT
Tidsramme: At least 4 years after the implantation
Incidence of abnormal findings on OCT.
At least 4 years after the implantation
Slit-lamp findings
Tidsramme: At least 4 years after the implantation
Incidence of abnormal slit lamp findings (eyelid, conjunctiva, epithelium, stroma, central cornea clarity, cornea neovascularization, anterior chamber, iris, lens).
At least 4 years after the implantation
Contrast sensitivity
Tidsramme: At least 4 years after the implantation
Determination of contrast sensitivity measured by CSV 1000 (Vector Vision) (changes from the pre-operative to the post-operative state and its stability over time will be investigated).
At least 4 years after the implantation
Defocus curve
Tidsramme: At least 4 years after the implantation
Change in visual acuity measured at different defocus vergence levels during monocular defocus curve testing over time.
At least 4 years after the implantation
Aberrometry measurements using iTrace
Tidsramme: At least 4 years after the implantation
Change in the total higher order aberrations (HOA) assessed by iTrace.
At least 4 years after the implantation
Subjective questionnaire QoV - patient satisfaction
Tidsramme: At least 4 years after the implantation
Evaluation of patient satisfaction assessed on a scale
At least 4 years after the implantation
Subjective questionnaire QoV
Tidsramme: At least 4 years after the implantation
Evaluation of patient satisfaction as assessed using the Quality of Vision (QoV) questionnaire scoring scale.
At least 4 years after the implantation
Adverse events incidence
Tidsramme: At least 4 years after the implantation
Intraoperative and adverse events at each time point (numbers and percentages)
At least 4 years after the implantation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Gemini Eye Clinic

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. juni 2025

Primær fullføring (Faktiske)

25. november 2025

Studiet fullført (Faktiske)

25. november 2025

Datoer for studieregistrering

Først innsendt

15. mai 2026

Først innsendt som oppfylte QC-kriteriene

28. mai 2026

Først lagt ut (Faktiske)

3. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CMG-PRT-002-1

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Presbyopi

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Liberia

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere